

CAVELIER

ABOGADOS

www.cavelier.com
cavelier@cavelier.com

EDIFICIO SISKI
CARRERA 4 No. 72 -
BOGOTA 8, COLOMBIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-040127-00006-0000

Fecha: 2008-07-16 17:11:03 Dep. 2020 NUECREACION
Tra. 11 PATENTE IYII Eve: 378 FASENACIONAL
Act. 538 PETICION Folios: 3

Señora Jefe de la
DIVISION DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. S. D.

Trámite : 011

Evento : 378

Actuación : 538

Referencia : Expediente No. 07.040.127
Asunto : Solicitud de Patente para **AGENTES BLOQUEADORES DE INTERFERON TIPO I PARA PREVENCION Y TRATAMIENTO DE PSORIASIS**
Solicitante : **UNIVERSITAT ZURICH**
Clase : A61K 039/395
Publicada en : La Gaceta No. **587** del 18 de enero de 2008
Fecha de Solicitud : 23 de abril de 2007

1. Yo, Emilio FERRERO, identificado como aparece al pie de mi firma, actuando como apoderado en el asunto de la referencia, atentamente, solicito se efectúe el examen de patentabilidad de la solicitud en referencia presentada de acuerdo con el Capítulo I del PCT y según lo establecido en el artículo 44 de la Decisión 486 de la Comisión de la Comunidad Andina. Para tal efecto presento junto con este escrito el recibo por valor de \$ 420.000.00, que corresponde a la tasa fijada según lo dispuesto en la resolución No. 44372 de 26 de diciembre de 2007.

2. Ruego atentamente a la Señora Jefe se sirva ordenar que se anexe este recibo para que se efectúe dicho examen y se continúe con el trámite de la solicitud.

Señora Jefe,

EMILIO FERRERO

T.P.A. No. 31.929

COLO-15885-841-001-8
SDC\SCT\ID-130392\WPC15885
No. M-2008-130392\SDC

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-040127- -00006-0000

Fecha: 2008-07-16 17:11:03 Dep. 2020 NUECREACION
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 538 PETICION Folios: 3

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 08 - 45,963
IA : JUNIO 9 DE 2008

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CAVELIER ABOGADOS	CONSIGNACION	BANCO DE BOGOTA	062754387	2678328	09/06/2008	89,445,000.00

***** CONCEPTO *****

1. RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1 50005-01-01 SOLICITUDES	114 PTC CAP-II EXAMEN DE PATENTIBILID	210,000.00
	TOTAL :	\$ 210,000.00

SON: DOSCIENTOS DIEZ MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

060 15885-841-001-8

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-040127 - 00006-0000

Fecha: 2008-07-16 17:11:03 Dep. 2020 NUECREACION
 Tra. 11 PATENTEIYII Eve. 378 FASENACIONAL
 Act. 538 PETICION Folios: 3

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 08 - 45,964
 IA : JUNIO 9 DE 2008

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CAVELIER ABOGADOS	CONSIGNACION	BANCO DE BOGOTA	062754387	2678328	09/06/2008	89,445,000.00

***** CONCEPTO *****

CONCEPTO	TOTAL CONCEPTO
1 50005-01-01 SOLICITUDES	114 PTC CAP-II EXAMEN DE PATENTIBILIDAD
	TOTAL : \$ 210,000.00

SDN: DOSCIENTOS DIEZ MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

Coto 15885-841-001-8

DIVISIÓN DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No. 07-40127

EL EXTRACTO DE LA PRESENTE SOLICITUD DE **PATENTE DE INVENCION**

FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No **587** DE

FECHA **18 DE ENERO DE 2008** EL TÉRMINO HÁBIL SEÑALADO POR LA LEY

EXPIRA EL **16 DE ABRIL DE 2008**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____

NO X

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/54721 A1

- (51) International Patent Classification⁷: **A61K 39/395**, C07K 14/715, A61K 9/00, A61P 37/06, A61K 38/17 // C07K 14/56, 14/565, 16/24, 14/715
- (21) International Application Number: PCT/GB01/00285
- (22) International Filing Date: 25 January 2001 (25.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0001710.3 25 January 2000 (25.01.2000) GB
- (71) Applicant (*for all designated States except US*): **PHARMA PACIFIC PTY LTD** [AU/AU]; Suite 6002, Bayside Plaza, 376 Bay Street, Brighton-le-Sands, NSW 2216 (AU).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **TOVEY, Michael, Gerard** [GB/FR]; 7, rue La Grange, F-75005 Paris (FR).
- (74) Agent: **IRVINE, Jonquil, Claire**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/54721 A1

(54) Title: ANTAGONIST OF TH-1 IMMUNERESPONSE INDUCING CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES

(57) Abstract: Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition of prevention of autoimmune diseases.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/00, 39/395, 39/44, C07K 16/24, 16/28	A1	(11) International Publication Number: WO 98/28001 (43) International Publication Date: 2 July 1998 (02.07.98)
(21) International Application Number: PCT/US97/24266 (22) International Filing Date: 22 December 1997 (22.12.97) (30) Priority Data: 08/771,831 23 December 1996 (23.12.96) US (71) Applicant: ADVANCED BIOTHERAPY CONCEPTS, INC. [US/US]; 802 Rollins Avenue, Rockville, MD 20852 (US). (72) Inventors: SKURKOVICH, Boris; 18 Blaisdell Avenue, Pawtucket, RI 02860 (US). SKURKOVICH, Simon, V.; 802 Rollins Avenue, Rockville, MD 20852 (US). (74) Agents: LEARY, Kathryn et al.; Panitch Schwarze Jacobs & Nadel, P.C., 22nd floor, One Commerce Square, 2005 Market Street, Philadelphia, PA 19103-7086 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TREATMENT OF AUTOIMMUNE DISEASES, INCLUDING AIDS (57) Abstract The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.		



US 20040067888A1

87

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2004/0067888 A1****Tovey et al.**(43) **Pub. Date: Apr. 8, 2004**(54) **THERAPEUTIC PEPTIDES****Publication Classification**(76) **Inventors: Michael Gerard Tovey, Paris (FR);
Pierre Eid, Paris (FR)**(51) **Int. Cl.⁷ A61K 38/10; A61K 38/08;
C07K 7/08; C07K 7/06**(52) **U.S. Cl. 514/14; 514/15; 530/327;
530/328****Correspondence Address:****ALSTON & BIRD LLP****BANK OF AMERICA PLAZA****101 SOUTH TRYON STREET, SUITE 4000****CHARLOTTE, NC 28280-4000 (US)**(57) **ABSTRACT**(21) **Appl. No.: 10/182,058**

The invention provides peptides of about 9-12 amino acids having a sequence derived from the interferon binding site of the IFNAR1 chain of the Type 1-interferon (Type 1-IFN) receptor for use as a Type 1-IFN antagonist. In particular, the invention provides peptides having the 9 mer sequence FSSLKLN¹VY (Sequence ID no. 1) and analogues thereof for use as Type 1-IFN antagonists. Particularly preferred for this purpose is the peptide of Sequence ID no. 1 and analogues thereof including Sequence ID no. 1 having an additional asparagine residue (N) at the C-terminus and/or additional glutamic acid residue (E) at the N-terminus.

(22) **PCT Filed: Jan. 25, 2001**(86) **PCT No.: PCT/GB01/00287**(30) **Foreign Application Priority Data****Jan. 25, 2000 (GB) 0001712.9**

Display Settings: Abstract

J Interferon Cytokine Res. 2004 Sep;24(9):560-72.

The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection.

Jones TD, Hanlon M, Smith BJ, Heise CT, Nayee PD, Sanders DA, Hamilton A, Sweet C, Unitt E, Alexander G, Lo KM, Gillies SD, Carr FJ, Baker MP.

Biovation Ltd., Babraham, Cambridge, UK. tim.jones@biovation.co.uk

Abstract

Interferon-alpha (IFN-alpha), in conjunction with ribavirin, is the current standard for the treatment of chronic hepatitis C virus (HCV) infection. This treatment requires frequent dosing, with a significant risk of the development of anti-IFN-alpha neutralizing antibodies that correlates with lack of efficacy or relapse. We have developed an IFN-alpha linked to the Fc region of human IgG1 for improved half-life and less frequent dosing. We have also identified, using a human T cell proliferation assay, three regions of IFN-alpha2b that are potentially immunogenic, and a variant containing a total of six mutations within these regions was made. This variant was made as a fusion to Fc either with or without a flexible linker between the fusion partners. Both configurations of the variant were less active than native IFN-alpha alone, although the variant containing the flexible linker had in vitro antiviral activity within the range of other modified IFN-alphas currently in clinical use. Peptides spanning the modified regions were tested in T cell proliferation assays and found to be less immunogenic than native controls when using peripheral blood mononuclear cells (PBMCs) from both healthy individuals and HCV-infected patients who had been treated previously with IFN-alpha2b.

Copyright Mary Ann Liebert, Inc.

PMID:15450132[PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

LinkOut - more resources